Quest Diagnostics to Offer FDA-Cleared Roche pTau217 Blood Test to Assess Alzheimer's Disease Pathology
Quest Diagnostics announced plans to add Roche's FDA-cleared Elecsys pTau217 blood test to its AD-Detect portfolio in the fourth quarter of 2026, marking the first FDA-cleared single-assay blood biomarker for Alzheimer's pathology assessment. Separately, the company will launch its own AD-Detect ABeta 42/40, p-tau217, and ApoE Evaluation lab-developed test by the end of August, featuring a lower 10% indeterminate rate compared to the industry benchmark of 15%-20%.
Key figures
- Launch roche test
- Q4 2026
- Indeterminate rate new
- 10%
- Patient service centers
- approximately 2,000
- Launch multi biomarker test
- end of August 2026
- Indeterminate rate benchmark
- 15%-20%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.